Acceptance and compliance with postpartum human papillomavirus vaccination

Obstetrics and Gynecology

Volumn 120, Issue 4, 2012, Pages 771-782

  Wright, Jason D ^a   Govindappagari, Shravya ^b   Pawar, Neha ^b   Cleary, Kirsten ^b   Burke, William M ^b   Devine, Patricia C ^b   Lu, Yu Shiang ^b   Tsai, Wei Yann ^b   Lewin, Sharyn N ^b   Herzog, Thomas J ^b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b Mailman School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; ARTICLE; DELIVERY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTPARTUM HUMAN PAPILLOMAVIRUS VACCINATION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; CHOICE BEHAVIOR; COHORT STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION SCHEDULE; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTPARTUM PERIOD; QUESTIONNAIRES; VACCINATION; YOUNG ADULT;

EID: 84866936298     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31826afb56     Document Type: Article

References (31)

1. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: A systematic review and meta-analysis. Lancet Oncol 2012;13: 487-500.
2. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prev Med 2011;53:S12-21.
3. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: A review. Aust N Z J Obstet Gynaecol 2011;51:103-8.
4. D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53: S5-11.
5. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
6. Drolet M, Brisson M, Maunsell E, Franco EL, Coutlée F, Ferenczy A, et al. The impact of anogenital warts on healthrelated quality of life: A 6-month prospective study. Sex Transm Dis 2011;38:949-56.
7. Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: A prospective study. Acta Obstet Gynecol Scand 2011;90:445-51.
8. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22.
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
10. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
11. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-11.
12. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berendsvan der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
13. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-85.
14. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
15. GlaxoSmithKline Vaccine HPV-007 Study Group; Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Texeira JC, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85.
16. Laz TH, Rahman M, Berenson AB. An update on human papillomavirus vaccine uptake among 11-17 year old girls in the United States: National Health Interview Survey, 2010. Vaccine 2012;30:3534-40.
17. Wong CA, Berkowitz Z, Dorell CG, Anhang Price R, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9-to 17-year-old girls: National Health Interview Survey, 2008. Cancer 2011;117:5612-20.
18. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1018-23.
19. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making 1995;15:25-30.
20. Goh AC, Kowalkowski MA, Bailey DE Jr, Kazer MW, Knight SJ, Latini DM. Perception of cancer and inconsistency in medical information are associated with decisional conflict: A pilot study of men with prostate cancer who undergo active surveillance. BJU Int 2012;110:E50-6.
21. Miller SM, Hudson SV, Egleston BL, Manne S, Buzaglo JS, Devarajan K, et al. The relationships among knowledge, self-efficacy, preparedness, decisional conflict, and decisions to participate in a cancer clinical trial. Psychooncology 2012 Feb 14 [Epub ahead of print]. DOI: 10.1002/pon.3043.
22. Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors associated with HPV vaccine uptake in teenage girls: A systematic review. Vaccine 2012;30:3546-56.
23. Agius PA, Pitts MK, Smith AM, Mitchell A. Human papillomavirus and cervical cancer: Gardasil vaccination status and knowledge amongst a nationally representative sample of Australian secondary school students. Vaccine 2010;28:4416-22.
24. Allen JD, Othus MK, Shelton RC, Li Y, Norman N, Tom L, et al. Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev 2010;19:2187-98.
25. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: Results of a national survey. J Adolesc Health 2009;45:453-62.
26. Chou B, Krill LS, Horton BB, Barat CE, Trimble CL. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol 2011;118:14-20.
27. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine 2010;28:989-95.
28. Gerend MA, Weibley E, Bland H. Parental response to human papillomavirus vaccine availability: Uptake and intentions. J Adolesc Health 2009;45:528-31.
29. Mathur MB, Mathur VS, Reichling DB. Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine status. J Pediatr Health Care 2010;24:14-24.
30. Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics 2011;127:77-84.
31. Hirth JM, Tan A, Wilkinson GS, Berenson AB. Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009. Cancer 2012 Apr 27 [Epub ahead of print]. DOI: 10.1002/cncr.27598.